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agonist/GnRH-antagonist protocol with




Recently, several new promising modifications have been introduced to clinical practice that may simplify and
optimize IVF outcome. In the present opinion paper we present a simplified approach to controlled ovarian
hyperstimulation protocol (COH), which combines the benefits of the ultrashort flare GnRH agonist/GnRH
antagonist protocol and the personalized tailored mode and timing of ovulation triggering, aiming to improve IVF
outcome while eliminating of severe OHSS.
In patients at risk to develop severe ovarian hyperstimulation syndrome (OHSS), GnRH agonist (GnRHa) trigger if
offered for final follicular maturation. While in those achieving ≥20 oocytes, the freeze all policy with the
subsequent frozen-thawed embryo transfers (ET) is recommended, in those where less than 20 oocytes are
retrieved, patients are re-evaluated 3 days after oocyte retrieval (day of ET) for signs of early moderate OHSS. If no
early signs of OHSS developed, one embryo was transferred, and the patients are instructed to inject 1500 IU of
HCG. In cases where signs of early moderate OHSS appear, the freeze all policy is recommended.
In Patients not at risk to develop severe OHSS- three different modes of concomitant administration of both GnRHa and
a standard bolus of hCG (5000–10,000 units) prior to oocyte retrieval were suggested. Standard hCG dose concomitant
with GnRHa (dual trigger), 35–37 h before oocyte retrieval is offered to normal responders patients, resulting in
improved oocyte/embryo quality and IVF outcome. GnRHa 40 h and standard hCG added 34 h prior to oocyte retrieval
(double trigger), respectively are offered to patients demonstrating abnormal final follicular maturation despite normal
response to COH. The double trigger results in significantly higher number of oocytes retrieved, higher proportions of
the number of oocytes retrieved to the number of follicles >10 mm and >14 mm in diameter on day of hCG
administration, higher number of MII oocytes and proportion of MII oocytes per number of oocytes retrieved, with the
consequent significantly increased number of top-quality embryos, as compared to the hCG-only trigger cycles.
Standard hCG dose concomitant with GnRHa (dual trigger), 34 h before oocyte retrieval should be offered to poor
responders patients, aiming to overcome premature luteinization, while achieving high yield of mature oocytes.
Further studies are required to support this new concept prior to its implementation as a universal COH protocol to IVF
practice.
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Background
Controlled ovarian hyperstimulation (COH) is consid-
ered a key factor in the success of in vitro fertilization-
embryo transfer (IVF-ET) because it enables the recruit-
ment of multiple healthy fertilizable oocytes and,
thereby, multiple as opposed to single ET. COH usually
includes the co-administration of gonadotropins and
gonadotropin-releasing hormone (GnRH) analogues; the
two most commonly used protocols are the long GnRH-
agonist (GnRHa) suppressive protocol and the multiple-
dose GnRH-antagonist (GnRHant) COH protocol. While
the advantages of using GnRH-ant, as opposed to
agonists include, mainly, a reduction in the incidence of
severe ovarian hyperstimulation syndrome (OHSS) [1],
when comparing pregnancy rates, the literature yields
conflicting results [2]. In addition, programming of
GnRHant cycles continues to be a challenge, and the use
of combined oral contraceptives (COCs) pretreatment,
which aims to achieve a better synchronized response
and a scheduled cycle, was associated with significantly
lower ongoing pregnancy rate, longer duration of the
stimulation and higher gonadotropin consumption [3].
Recently, several new promising modifications have
been introduced to clinical practice, of which, the ultra-
short flare GnRHa/GnRHant protocol and the different
mode and timing of hCG and GnRHa co-administration
for final follicular maturation, have the most prominent
impact on IVF outcome.
Prompted by the aforementioned observations, in our
center, conducting up to 1200 IVF cycles per year, we
have started to implement a simplified approached to
COH protocol. The present opinion paper aims to
present this simplified approach (Fig. 1), which com-
bines the benefits of the ultrashort flare GnRHa/
GnRHant protocol and the personalized tailored mode
and timing of ovulation triggering. We believe that its
universal implementation to IVF practice will result in
improved outcome while allowing the elimination of
severe OHSS.
The ultrashort flare GnRHa/GnRHant protocol
The ultrashort flare GnRHa/GnRHant protocol was re-
cently introduced to the COH protocols armamentarium
[4]. It offers all the advantages of using GnRHant, in-
cluding a lack of hypoestrogenism, shorter treatment
duration and lower gonadotropin requirement. More-
over, it allows cycle programming and offers successful
outcome in a variety of challenging cases such as poor
responders, and patients with poor embryo quality or re-
peated IVF failures [5–7]. In addition, this protocol pro-
vides protection from severe OHSS by maintaining the
option to substitute hCG with GnRHa for final follicular
maturation in patients at risk of OHSS [8].
The protocol is comprised of the administration of
COCs started on days 2–5 of the menses continued for
at least 7 days. GnRHa (e.g. triptorelin 0.1 mg/day) is
commenced 3 days after the cessation of the COCs,
followed by gonadotropins (FSH only preparations) initi-
ated two days later. GnRHant is added according to the
individual program policy (fixed or flexible), and contin-
ued until the day of triggering final oocytes maturation.
On the day of GnRHant initiation, LH is added to the
FSH only preparations.
Final follicular maturation is triggered as soon as the
majority of the leading preovulatory follicles have
reached a diameter of 17 mm, preferably with a ratio of
E2 level to number of leading preovulatory follicles of
>14 mm calculated to be lower than 100 pg/mL [9]. All
patients should receive luteal support with progesterone
starting on the day following oocyte retrieval.
Fig. 1 A simplified approach/algorithm to COH protocol, which combines the ultrashort flare GnRHa/GnRHant protocol and the personalized
tailored timing of ovulation triggering
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Triggering final follicular maturation
Recently, different modes and timing of ovulation trig-
gering, using GnRHa, hCG, or both, were adopted to
clinical practice [10], attempting to either rescuing the
luteal phase and improving reproductive outcome in
patients at risk to develop severe OHSS, or improving
oocyte/embryo yield and quality in the general IVF
population or in patients with abnormal final follicular
maturation.
COH using GnRHa trigger has become a common
tool aiming to eliminate severe early OHSS and to sup-
port the concept of an OHSS-free clinic. However, due
to the reported significantly reduced clinical, efforts have
been made to improve reproductive outcome. Moreover,
while comparing the effect of hCG versus GnRHa trigger
on the different follicular maturation variables following
an IVF treatment cycle, studies have revealed that the
number of oocytes retrieved, percentage of mature oo-
cytes and number of top-quality embryos were either
comparable or in favor of the GnRHa trigger.
These advantages were related to the concomitant
midcycle FSH peak, observed following GnRHa trigger.
The later ensures an adequate complement of LH recep-
tors on the granulosa layer and the synthesis of hyalur-
onic acid matrix that facilitates the expansion and
dispersion of the cumulus cells, allowing the oocyte-
cumulus cell mass to become free-floating in the antral
fluid [11]. Moreover, while studying the downstream ef-
fects of LH receptor activation by LH or hCG, it was
demonstrated that LH has a greater impact on AKT and
extracellular signal regulated protein kinase (ERK1/2)
phosphorylation, responsible for granulosa cells prolifer-
ation, differentiation and survival, while hCG generates
higher intracellular cAMP accumulation, which stimu-
lates steroidogenesis (progesterone production) [12].
Following the aforementioned observations, GnRHa
combined with hCG trigger- for final follicular matur-
ation has been implemented to clinical practice, and the
different modes and timing of administration should be
appropriately tailored to various subgroup of IVF
patients.
The rationale behind the different stages of the
suggested universal protocol
COC
The ultrashort flare GnRHa/GnRHant protocol is com-
prised of the administration of COCs started on days 2–5
of the menses continued for at least 7 days. COCs pretreat-
ment was shown to result in a better synchronized response
and a scheduled cycle on one hand, with significantly lon-
ger duration of the stimulation, higher gonadotropin con-
sumption and a questionable lower ongoing pregnancy
rate [3, 13, 14]. The detrimental effect of pretreatment
COCs in the GnRH antagonist protocol was related to the
potential negative effect of the gestagen component on
the endometrium, or the low endogenous LH levels in-
duced by COCs, with their deleterious impact on oocyte
competence or endometrial receptivity [13].
Regarding the detrimental effects of the gestagen
component of the COCs. Recently, the use of anti-
androgenic COCs (drospirenone, cyproterone acetate) in
oocytes donors was demonstrated to result in a significantly
higher oocytes yield, as compared to those using andro-
genic COCs, and a comparable yield to donors with no
COCs pre-treatment. Differences that were maintained also
after adjustments for the donor age and total FSH dose
used in ovulation induction [15].
Repeated IVF failures
When applied to patients with repeated IVF failures, the
combination of diagnostic hysteroscopy and endometrial
sampling during COCs treatment, which precedes the
ultrashort GnRH-ag/GnRH-ant protocol, should be offered,
resulting in an improved outcome with high implantation
and clinical pregnancy rates (42 % as compared to 25 % in
patients’ previous conventional IVF cycle) [7].
The ultrashort flare GnRH-agonist
The ultrashort flare GnRH-agonist stimulates an early
follicular phase endogenous FSH release without the
concomitant deleterious rises in androgen levels or cor-
pus luteum rescue [16], which is fundamental for follicu-
lar recruitment. Moreover, the pretreatment with OCPs
was recently shown to suppress pre-GnRH-agonist FSH
without blunting the FSH flare and therefore should not
affect the follicular response to the GnRH agonist flare.
Furthermore, since COC pretreatment blunts the LH
flare, thus preventing the detrimental effect of GnRH-
agonist induced early rise in follicular androgens with
the consequent increase in serum progesterone levels
[17], COC should be offered to all patients undergoing
the GnRH-agonist flare protocol.
The combination of COCs pretreatment COCs with
the microdose flare protocol, which has been offered to
poor-responder patients for almost three decades, dem-
onstrated similar results when compared with various
other COH protocols, with improved cycle parameters
and decreased cancellation rates [16]. This probably re-
sults from the flare effect which overcomes the endogen-
ous gonadotropins suppression by the COCs and the
aforementioned consequent deleterious impact on oo-
cyte competence or endometrial receptivity.
The GnRH-antagonist
The GnRH-antagonist provides immediate LH suppres-
sion with the possible improvement of the quality of the
blastocysts generated [18].
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Triggering final follicular maturation by GnRH-agonist
Triggering final follicular maturation by GnRH-agonist,
in patients at high risk to develop severe OHSS undergo-
ing the ultrashort GnRH ag/GnRH ant protocol, was
shown to be feasible option [8]. The 3 consecutive doses
of daily GnRH-a agonist administration at the beginning
of ultrashort GnRH-ag/GnRH-ant COH protocol, did not
interfere with the ability of the GnRH-agonist to trigger
final oocytes maturation at the end of the COH cycle and
did not compromise IVF outcome [8, 19].
The aforementioned observation implies that in pa-
tients undergoing COH using the ultrashort GnRH-ag/
GnRH-ant COH protocol, final follicular maturation
may be triggered with hCG, GnRHa or both.
A simplified approach/algorithm to COH protocol (Fig. 1)
Patients at risk to develop severe OHSS
Patients at risk to develop severe OHSS, those with rap-
idly rising serum E2 levels; peak E2 level in excess of
2500 pg/mL; and/or the emergence of a large number of
intermediate sized follicles [20], GnRHa trigger if offered
for final follicular maturation. In those achieving ≥20 oo-
cytes, the freeze all policy with the subsequent frozen-
thawed embryo transfers (ET) is recommended.
If less than 20 oocytes are retrieved, patients are
instructed to start an intensive luteal support with estra-
diol and progesterone, the day following OPU, and are
re-evaluated 3 days after oocyte retrieval (day of ET) for
signs of early moderate OHSS (ultrasonographic signs of
ascites as reflected by the appearance of fluid surround-
ing the uterus/ovaries, and/or Hct levels >40 % for the
degree of haemoconcentration). The intensive luteal
support includes 4 mg daily E2 valerate per os (Progy-
nova; Schering), combined with either 50 mg progester-
one IM (Gestone, Ferring- Lapidot, Israel) daily, 400 mg
micronized progesterone vaginal tablets (Endometrin,
Ferring-Lapidot, Israel) in two divided doses, 900 mg
micronized progesterone soft gel vaginal capsules
(Utrogestan, Besins, Iscovesco, C.T.S., Petach Tikva,
Israel) in three divided doses, or 180 mg micronized
progesterone vaginal gel (Crinone® 8 %, Merck Serono,
Herzelia, Israel) in two divided doses.
If no early signs of OHSS developed, one embryo was
transferred, and the patients are instructed to inject
1500 IU of HCG [21]. By deferring the hCG bolus by
3 days (5 days following GnRHa trigger), the corpus
luteum is rescued, with an observed extremely high mid-
luteal progesterone levels [22], reasonable pregnancy
rate, with no patient developing severe OHSS. Moreover,
by deferring the hCG bolus, we are actually offering the
hCG to 80 % of the a priori at risk patients, who are not
supposed to develop severe early OHSS, while avoiding
hCG administration to the “real” 20–26 % [23, 24] pa-
tient at risk to develop severe early-OHSS.
In cases where signs of early moderate OHSS appear,
the freeze all policy is recommended.
Patients not at risk to develop severe OHSS
Three different modes of concomitant administration of
both GnRHa and a standard bolus of hCG (5000–10,000
units) prior to oocyte retrieval were suggested, aiming to
improve oocyte and embryo quantity and quality and
the consequent IVF cycle outcome. Luteal support con-
sists of progesterone only, in the forms of either 200 mg
micronized progesterone vaginal tablets (Endometrin,
Ferring-Lapidot, Israel) in two divided doses, 600 mg
micronized progesterone soft gel vaginal capsules (Utro-
gestan, Besins, Iscovesco, C.T.S., Petach Tikva, Israel) in
three divided doses, or 90 mg micronized progesterone
vaginal gel (Crinone® 8 %, Merck Serono, Herzelia,
Israel) once a day.
Standard hCG dose concomitant with GnRHa (dual
trigger), 35-37 h before oocyte retrieval is offered to nor-
mal responders patients, resulting in higher number of
oocytes retrieved [25], matured oocytes [25, 26] and
number of embryos cryopreserved [25, 27], with the
consequent significant increase in implantation [23],
clinical pregnancy and live-birth rates [25] and the num-
ber of patients who received at least one embryo of ex-
cellent quality [27], as compared with the hCG-only
trigger group [25–27].
GnRHa 40 h and standard hCG added 34 h prior to
OPU (double trigger), respectively are offered to two
group of patients demonstrating abnormal final follicular
maturation despite normal response to COH, those with
low (<50 %) number of oocytes retrieved per number of
dominant follicles > 14 mm in diameter on day of hCG
administration [28] and those with low proportion of
mature/ metaphase-II (MII) oocytes (<66 %) per number
oocytes retrieved [29]. In both groups, following the
double trigger, patients had significantly higher number
of oocytes retrieved, higher proportions of the number
of oocytes retrieved to the number of follicles >10 mm
and >14 mm in diameter on day of hCG administration,
higher number of MII oocytes and proportion of MII
oocytes per number of oocytes retrieved, with the
consequent significantly increased number of top-
quality embryos, as compared to the hCG-only trigger
cycles [28, 29]. This regimen was based on the as-
sumption, that by prolonging the time between ovula-
tion triggering and OPU and the GnRHa trigger with
the consequent simultaneous induction of an FSH
surge, the “double trigger” could overcome any existing
impairments in granulosa cell function, oocyte meiotic
maturation or cumulus expansion [30].
Standard hCG dose concomitant with GnRHa (dual
trigger), 34 h before oocyte retrieval should be offered
to poor responders patients. One of the major
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unnoticed concern in poor responders is the observed
high prevalence of premature luteinization\ovulation
[31, 32]. This may be overcome by early triggering of
final follicular maturation- while approaching a fol-
licular size of 15–16 mm, and by shortening the dur-
ation between the trigger and OPU. However, since
shortening the interval between hCG priming and oocyte
retrieval may decrease the percentage of mature oocytes
[33], dual trigger (hCG and GnRHa) administered 34 h
prior to OPU will provide the additional improvement in
the number of oocytes retrieved to the number of follicles
>10 mm, and the proportion of mature oocytes should be
implemented [28, 29].
Conclusion
In the present opinion paper we suggested and discussed
a simplified approach to COH protocol, which combines
the benefits of the ultrashort flare GnRHa/GnRHant
protocol and the personalized tailored mode and timing
of triggering final follicular maturation in IVF patients.
Further studies are required to support this new concept
prior to its universal implementation to IVF practice.
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